Literature DB >> 29392480

Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients.

Heather L Gelhorn1, Anne M Skalicky2, Zaneta Balantac2, Sonya Eremenco2, Tricia Cimms3, Katarina Halling4, Patricia J Hollen5, Richard J Gralla6, Martin C Mahoney7, Chris Sexton2.   

Abstract

PURPOSE: Obtaining qualitative data directly from the patient perspective enhances the content validity of patient-reported outcome (PRO) instruments. The objective of this qualitative study was to evaluate the content validity of the Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso) and its usability on an electronic device.
METHODS: A cross-sectional methodological study, using a qualitative approach, was conducted among patients recruited from four clinical sites. The primary target population included patients with pleural mesothelioma; data were also collected from patients with peritoneal mesothelioma on an exploratory basis. Semi-structured interviews were conducted consisting of concept elicitation, cognitive interviewing, and evaluation of electronic patient-reported outcome (ePRO) usability.
RESULTS: Participants (n = 21) were interviewed in person (n = 9) or by telephone (n = 12); 71% were male with a mean age of 69 years (SD = 14). The most common signs and symptoms experienced by participants with pleural mesothelioma (n = 18) were shortness of breath, fluid build-up, pain, fatigue, coughing, and appetite loss. The most commonly described symptoms for those with peritoneal mesothelioma (n = 4) were bloating, changes in appetite, fatigue, fluid build-up, shortness of breath, and pain. Participants with pleural mesothelioma commonly described symptoms assessed by the LCSS-Meso in language consistent with the questionnaire and a majority understood and easily completed each of the items. The ePRO version was easy to use, and there was no evidence that the electronic formatting changed the way participants responded to the questions.
CONCLUSIONS: Results support the content validity of the LCSS-Meso and the usability of the electronic format for use in assessing symptoms among patients with pleural mesothelioma.

Entities:  

Keywords:  HRQL; Lung Cancer Symptom Scale for Mesothelioma (LCSS-Meso); Patient-reported outcome; Symptoms

Mesh:

Year:  2018        PMID: 29392480     DOI: 10.1007/s00520-018-4061-0

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  11 in total

1.  Palliative care research: methodological and ethical challenges.

Authors:  Ruth A Dean; Susan E McClement
Journal:  Int J Palliat Nurs       Date:  2002-08

2.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-13       Impact factor: 5.725

3.  Mesothelioma from the patient's perspective.

Authors:  Helen Clayson; Jane Seymour; Bill Noble
Journal:  Hematol Oncol Clin North Am       Date:  2005-12       Impact factor: 3.722

4.  Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.

Authors:  Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

Review 5.  The worldwide pandemic of asbestos-related diseases.

Authors:  Leslie Stayner; Laura S Welch; Richard Lemen
Journal:  Annu Rev Public Health       Date:  2013-01-04       Impact factor: 21.981

6.  Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL).

Authors:  Patricia J Hollen; Richard J Gralla; John A Stewart; Jacinta M Meharchand; Rafal Wierzbicki; Natasha Leighl
Journal:  Support Care Cancer       Date:  2012-06-10       Impact factor: 3.603

Review 7.  Living with mesothelioma. A literature review.

Authors:  S Moore; L Darlison; A M Tod
Journal:  Eur J Cancer Care (Engl)       Date:  2009-10-14       Impact factor: 2.520

8.  Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.

Authors:  Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

9.  Perspectives on patient-reported outcomes : content validity and qualitative research in a changing clinical trial environment.

Authors:  Nancy Kline Leidy; Margaret Vernon
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report.

Authors:  Margaret Rothman; Laurie Burke; Pennifer Erickson; Nancy Kline Leidy; Donald L Patrick; Charles D Petrie
Journal:  Value Health       Date:  2009-09-25       Impact factor: 5.725

View more
  2 in total

1.  Using Electronic Data Collection Platforms to Assess Complementary and Integrative Health Patient-Reported Outcomes: Feasibility Project.

Authors:  Jolie N Haun; Amy C Alman; Christine Melillo; Maisha Standifer; Julie McMahon-Grenz; Marlena Shin; W A Lapcevic; Nitin Patel; A Rani Elwy
Journal:  JMIR Med Inform       Date:  2020-06-26

2.  Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Authors:  Tito R Mendoza; Loretta A Williams; Karen N Keating; Jonathan Siegel; Cem Elbi; Anna K Nowak; Raffit Hassan; Brian Cuffel; Charles S Cleeland
Journal:  J Patient Rep Outcomes       Date:  2019-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.